48-year-old woman with recurrent ductal carcinoma in situ (DCIS) in left breast

 

48-year-old woman with recurrent ductal carcinoma in situ (DCIS) in left breast. A. Mammographic magnification view shows grouped calcifications in left breast (circle). Stereotactic biopsy yielded grade 2 DCIS. Patient underwent lumpectomy with tumor-negative surgical margins and radiation therapy. B. Mammographic magnification view obtained 4 years after diagnosis shows new calcifications at surgical site (circle). Stereotactic biopsy was performed, which revealed recurrent grade 2 DCIS. Patient then underwent mastectomy.


December 26, 2023 — Results published in the American Journal of Roentgenology (AJR) support mammographic surveillance protocol for patients with a previous breast cancer diagnosis of returning immediately to digital breast tomosynthesis (DBT) screening.

“Although the abnormal interpretation rate (AIR) was higher during the year after diagnosis compared to subsequent years, the AIR remained acceptably low (< 10%) in all years,” concluded lead investigator Dan Do, BA, from Massachusetts General Hospital in Boston.  

This AJR accepted manuscript included 8,090 patients (mean age, 65 years) with a prior breast cancer diagnosis who underwent 30,812 screening DBT examinations during Do et al.’s study period. The cancer detection rate (CDR) was 8.6 per 1,000 examinations, AIR was 5.7%, PPV 1 was 15.1%, sensitivity was 80.3%, specificity was 95.1%, and false-negative rate was 2.1%.

Ultimately, CDR showed a significant independent positive association with years since breast cancer diagnosis (adjusted OR 1.03, 95% CI 1.01-1.05, p<.001). Meanwhile, AIR evidenced significant independent negative association with years since breast cancer diagnosis (adjusted OR 0.99, 95% CI 0.98-1.00, p=.01)—being highest less than or equal to 1 year after diagnosis (7.5%) and lowest greater than 5, but less than 6 years postdiagnosis (5.0%).

For more information: www.arrs.org


Related Content

News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — Susan G. Komen, the world’s leading breast cancer organization commends Assemblymember Lori Wilson (D ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — iSono Health has announced the commercial launch of ATUSA, an FDA-cleared, wearable and automated 3D ...

Time January 14, 2026
arrow
News | Women's Health

Dec. 12. 2025 — A new study has found that an individualized approach to breast cancer screening that assesses patients’ ...

Time December 17, 2025
arrow
Subscribe Now